Risk factor
Good trading liquidity
Profitability factor
Undervalued vs peers
About
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors;...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/EB
Target Price
The average target price of 2186.HK is 3.6 and suggests 30% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell